8-K: Skye Bioscience: Mixed Phase 2a Nimacimab Data

Skye Bioscience's nimacimab monotherapy failed its primary weight loss endpoint, but showed clinically meaningful additional weight loss in combination with semaglutide, with a favorable safety profile.

Summary

• Nimacimab monotherapy (200 mg weekly) did not meet its primary endpoint for weight loss, showing -1.52% vs. -0.26% for placebo (mITT).
• Preliminary pharmacokinetic analysis indicated lower than expected drug exposure for monotherapy, suggesting a need for higher dosing.
• Nimacimab (200 mg weekly) combined with semaglutide achieved -13.2% weight loss compared to -10.25% for semaglutide alone (p=0.0372, mITT), representing a -2.95% additional weight loss.
• No plateau in weight loss was observed in the combination arm through Week 26, indicating potential for further loss.
• In the per protocol analysis for the combination arm, 100% achieved >5% weight loss (vs. 85% with semaglutide alone) and 67% achieved >10% weight loss (vs. 50% with semaglutide alone).
• Nimacimab, both alone and in combination, demonstrated a clean safety profile with placebo-like tolerability.
• No increase in gastrointestinal (GI) adverse events was observed when combined with semaglutide (57.1% vs. 66.7% for semaglutide alone).
• No nimacimab-associated neuropsychiatric adverse events (anxiety, insomnia, depression) were reported.
• An improvement in lean mass to fat mass ratio was observed in the combination arm compared to placebo (0.26 vs. 0.02, p <0.0001) and semaglutide alone (0.26 vs. 0.13, p = 0.0126).
• The overall discontinuation rate for the CBeyondTM study was 27%, with 3.7% due to adverse events, 60% of which were in the placebo group.

Sentiment

Score: 6

Explanation: The mixed results present a complex picture. While monotherapy failed, the strong performance and safety profile of the combination therapy, especially the additive weight loss to semaglutide without increased side effects, is a significant positive. The need for higher dosing in monotherapy and the small sample size for combination are caveats, but the potential for a differentiated combination therapy is promising.

Positives

• Clinically meaningful additional weight loss of -2.95% observed with nimacimab plus semaglutide compared to semaglutide alone (-13.2% vs -10.25%, p=0.0372).
• No plateau in weight loss was observed in the combination arm through Week 26, suggesting potential for further efficacy.
• Nimacimab demonstrated a clean safety profile with placebo-like tolerability, both as monotherapy and in combination.
• No increase in gastrointestinal (GI) adverse events when combined with semaglutide (57.1% vs. 66.7% for semaglutide alone).
• No nimacimab-associated neuropsychiatric adverse events (anxiety, insomnia, depression) were reported.
• Improved lean mass to fat mass ratio in the combination arm compared to semaglutide alone (0.26 vs. 0.13, p = 0.0126).
• High frequency of responders in the combination arm (per protocol analysis: 100% achieved >5% weight loss vs. 85% with semaglutide; 67% achieved >10% weight loss vs. 50% with semaglutide).

Negatives

• Nimacimab monotherapy (200 mg weekly) did not meet its primary endpoint for weight loss compared to placebo (-1.52% vs. -0.26%).
• Preliminary pharmacokinetic analysis showed lower than expected drug exposure for the 200 mg monotherapy dose, potentially limiting its observed effect.

Risks

• Initiation and design of future clinical trials will be impacted by capital resources and the ability to obtain additional sources of capital.
• Preliminary pharmacokinetic and dose-exposure analysis is not complete and such analysis may change.
• The potential for additional weight loss after 26 weeks may not ultimately be observed.
• There is no guarantee that higher dosing of nimacimab will achieve increased efficacy, and higher dosing could produce adversely different safety and tolerability results.
• Dependence on third parties for product manufacturing, research, and preclinical and clinical testing.
• Ability to advance, obtain regulatory approval of, and ultimately commercialize nimacimab.
• Competitive products or approaches could limit the commercial value of nimacimab.
• Uncertainty regarding the timing and results of preclinical and clinical trials.
• Ability to fund development activities and achieve development goals.
• Impact of global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, and adverse regulatory changes.
• Ability to protect intellectual property.
• Risks associated with the company's common stock.

Future Outlook

Skye Bioscience believes multiple factors support evaluating nimacimab at higher doses, including preclinical toxicology margins, modeling, and the notable safety profile. The company is evaluating next steps, including a potential follow-on Phase 2 study beyond the ongoing Phase 2a extension. Data from the extension study is expected in Q1 2026. Detailed results from the 26-week treatment period will be presented at ObesityWeek in November.

Management Comments

• "The 200 mg monotherapy arm provided important pharmacokinetic insight, showing that lower-than-expected drug exposure may have limited the observed effect and informing the dose-ranging strategy we are developing." Puneet Arora, MD, FACE, Chief Medical Officer.
• "At the same time, the combination of nimacimab with semaglutide produced a clinically meaningful additional weight loss that exceeded semaglutide alone, with a favorable tolerability profile even in patients who achieved the highest exposure levels." Puneet Arora, MD, FACE, Chief Medical Officer.
• "With our preclinical data, toxicology safety margins, and PK modeling, we believe we have a path to support higher dosing, and we are evaluating the next stage of development to optimize dosing in potential future clinical trials." Puneet Arora, MD, FACE, Chief Medical Officer.
• "This is the first clinical study to show that the combination of a CB1 inhibitor and a GLP-1 therapeutic can drive clinically meaningful additional weight loss beyond a GLP-1 drug alone." Louis Aronne, MD, clinical advisor.
• "Equally important, although the sample size is small, nimacimab achieved this without neuropsychiatric or additive gastrointestinal adverse events. I believe these results warrant further evaluation of the therapeutic potential of this novel CB1 inhibitor." Louis Aronne, MD, clinical advisor.
• "It was notable that nimacimab did not increase GI adverse events while adding clinically meaningful weight loss in combination with semaglutide. In my view, a next study with higher nimacimab dosing is the logical step to fully define its role in clinical practice." Sean Wharton, MD, clinical advisor.

Industry Context

The obesity treatment market is rapidly expanding, driven by the success of GLP-1 receptor agonists like semaglutide (Wegovy). These drugs are highly effective but often associated with gastrointestinal side effects. Nimacimab, as a peripherally-restricted CB1 inhibitor, aims to offer an additive benefit to GLP-1s without increasing these adverse events, addressing a significant unmet need for enhanced efficacy and improved tolerability in combination therapies. This approach seeks to differentiate from existing treatments and overcome the safety concerns associated with older, centrally-acting CB1 inhibitors.

Comparison to Industry Standards

• Semaglutide (Wegovy) alone typically achieves around 15% weight loss in clinical trials over 68 weeks. The -10.25% observed in the semaglutide-alone arm over 26 weeks is consistent with the expected trajectory for GLP-1s at this timeframe.
• The additional -2.95% weight loss from nimacimab in combination with semaglutide, reaching -13.2% total at 26 weeks, suggests a potentially superior efficacy profile compared to semaglutide monotherapy at this stage.
• The absence of increased GI or neuropsychiatric adverse events with nimacimab, especially compared to historical centrally-acting CB1 inhibitors like Rimonabant (which was withdrawn due to severe psychiatric side effects), highlights a significant safety advantage and differentiation.

Stakeholder Impact

• Shareholders: Potential for increased value if combination therapy proves successful in larger trials, but risk from monotherapy failure and the stated need for future capital.
• Patients: Potential for a new, more effective, and well-tolerated combination therapy for obesity, especially for those seeking greater weight loss than GLP-1s alone or who experience side effects.
• Competitors: Introduces a novel mechanism (peripheral CB1 inhibition) that could differentiate from existing GLP-1s and other obesity drugs.

Next Steps

• Evaluate the data to determine next steps, including a potential follow-on Phase 2 study beyond the ongoing Phase 2a extension study.
• Optimize dosing in potential future clinical trials.
• Present the next set of detailed results from the 26-week treatment period of the CBeyondTM trial at ObesityWeek in November.
• Report data from the Phase 2a extension study in Q1 2026.

Key Dates

Recommendation

The monotherapy failure is a significant setback, but the positive results from the combination therapy with semaglutide, particularly the additive weight loss without increased GI or neuropsychiatric side effects, present a compelling path forward. The small sample size of the combination arm and the need for higher dosing in future studies introduce uncertainty. Investors should hold to await further data from the extension study and details on the next phase of development, especially regarding optimized dosing and larger trial outcomes, before making a definitive investment decision. The potential for a differentiated combination therapy is strong, but the risks associated with further clinical development and capital needs are notable.

Keywords

Skye Bioscience, SKYE, Nimacimab, CB1 inhibitor, Semaglutide, GLP-1, Obesity, Metabolic health, Phase 2a, Clinical trial, Weight loss, Pharmacokinetics, Safety profile, Neuropsychiatric, Gastrointestinal, Biotechnology, Drug development